PacBio (PACB) Q3 2026 earnings review
PacBio places more sequencers, but its chemical sales shrink
PacBio sold more gene-sequencing machines this quarter while revenue from the chemical kits that run inside them shrank. Total sales rose 6% to $40.6 million and recent job cuts narrowed the operating loss, yet gross margin excluding one-offs dropped 6 percentage points on computer memory costs and factory moves. Chief executive Mark Van Oene also took over as interim finance chief after Jim Gibson stepped down, and the company cut the top of its full-year revenue plan for a third straight quarter, which by our math points to a 9% sales drop in the fourth quarter.
| Revenue | $40.6M +5.5% from a year ago |
|---|---|
| Consumable revenue | $20.8M -2.3% from a year ago |
| Spending per Revio machine | ~$204K ~$236K a year ago |
| Full-year revenue outlook | Cut $2.5M middle of the range: -1.6% from 2025 |
⚖️ Verdict: 🔴 Bearish
The story got worse because fast adoption of PacBio's cheaper reusable chemistry did not lift chemical sales or the full-year plan. Two-thirds of Revio customers upgraded their software for the new kits — beating the company's own third-quarter goal — yet annual chemical spending per machine stayed near $204,000 and total consumable sales fell from a year ago. One bright spot: the July layoffs lowered operating expenses excluding one-offs by 13% from a year ago.
The question now is whether the 30% lower price per genome permanently shrinks revenue per machine or whether customers are still working through old supplies before ordering more. If higher testing volume makes up for the lower price, chemical spending per machine will climb back toward $225,000; if it does not, revenue stays flat even as the fleet grows. Fourth-quarter consumable sales and the initial 2027 outlook will tell.
🐂 Bull Case
Job Cuts Lowered Operating Costs by 13%
PacBio makes gene-sequencing machines and the chemical kits that run inside them, and it has cut staff three times in two years to reduce its losses. Those cuts lowered operating costs excluding one-offs by 12.9% from a year ago to $47.0 million, which narrowed the net loss excluding one-offs from $36.8 million to $32.8 million.
- Research and development: 49.9% of revenue, down 9.6 percentage points from a year ago
- Sales, general and administrative: 72.5% of revenue, down 8.4 percentage points from a year ago
- Restructuring charges in the quarter: $3.0 million, mainly for severance
The company credited "lower personnel and related expenses, resulting from PacBio’s restructuring initiatives". Spending fell by $9.2 million from the second quarter alone, so the July layoffs are already reducing the quarterly bill.
What to watch: fourth-quarter operating expenses excluding one-offs. Keeping the quarterly bill near $47 million will show whether the savings hold without hurting sales.
New Clinical Deals and Sequencer Shipments Grow
PacBio wants hospitals and large research programs to rely on HiFi, its technology for reading long stretches of DNA at high accuracy. Instrument revenue rose 16.8% from a year ago to $13.2 million because the company delivered 15 high-capacity Revio machines and 35 benchtop Vega systems, with more than 90% of the Vega units going to new customers.
The company also partnered with genetic-testing provider GeneDx to "deepen PacBio’s role in rare disease and support PacBio's priority to grow clinical work". In addition, it signed population-research and artificial-intelligence deals with Berry Genomics in China, the Department of Veterans Affairs, Verily Health and TychoBio, which builds the customer base for future chemical sales.
What to watch: Revio and Vega placements in the fourth quarter. Steady shipments above 15 Revio units will show whether hospital demand is holding up.
🐻 Bear Case
New Chemistry Adoption Beats Target, Consumables Shrink
"SPRQ-Nx is changing the economics of HiFi sequencing, while growing clinical adoption and strategic collaborations in population genomics and AI are expanding the markets we can serve," chief executive Mark Van Oene said. SPRQ-Nx is PacBio's new chemical kit that lets customers reuse a sequencing chip to cut the price of reading a human genome by about 30%.
Customers adopted the software upgrade for SPRQ-Nx faster than planned: two-thirds of Revio machines had the upgrade by September, beating the company's goal of half. In late August, the genetics group also launched the chemistry on its smaller Vega machine.
Yet consumable revenue — the chemical kits that carry the growth story — fell 2.3% from a year ago to $20.8 million, turning negative after growing in the first half. Annualized consumable spending per Revio machine was about $204,000, down 13.6% from $236,000 a year ago and barely above last quarter's $202,000. Lower prices per run are cutting revenue per machine faster than extra customer testing is adding to it.
What to watch: annualized spending per Revio machine in the fourth quarter. A reading stuck near $204,000 now that two-thirds of machines use the new kits would show that volume is not making up for the price cut.
Third Outlook Cut Points to Fourth-Quarter Drop
PacBio lowered the top of its 2026 revenue forecast for the third quarter in a row, cutting the range from $155–165 million to $155–160 million. The life-science company started the year expecting $165–180 million, so the middle of the plan has fallen by $15 million in nine months.
With $116.7 million booked in the first nine months, by our math the new outlook leaves $38.3–43.3 million for the fourth quarter. At the middle of the range, fourth-quarter sales would be $40.8 million, flat from the third quarter and down 8.7% from $44.6 million a year ago. That leaves none of the late-year reorder wave the company had pointed to earlier in the year.
What to watch: the initial 2027 revenue outlook on the fourth-quarter release. A target near $160 million would show that the lower price of SPRQ-Nx is keeping a lid on total growth.
Cash Burn and Finance Chief Exit Add Pressure
PacBio ended September with $199.4 million in cash and investments, down $37.5 million in three months by our math, against $643.1 million of convertible debt due in 2029 and 2030. Excluding $48.1 million from selling its short-read assets in January, the business has burned $128.2 million of cash in nine months by our math.
At the same time, finance chief Jim Gibson stepped down, and Van Oene took over as interim finance chief just three months after becoming chief executive. In addition, third-quarter restructuring charges reached $3.0 million, above the roughly $2.0 million the company had planned when it announced the job cuts in July.
What to watch: year-end cash and investments against the $175–185 million target set last quarter. A balance below $175 million would mean cash burn stayed above $24 million in the fourth quarter.
Memory Costs and Factory Moves Cut Gross Margin
Gross margin excluding one-offs fell 6 percentage points from a year ago to 36%, matching the second quarter's level. The company blamed "higher memory costs and Vega manufacturing transition costs" as it brings production of the Vega benchtop sequencer in-house from a contract manufacturer.
On the income statement, the cost of making products rose by 3.8 percentage points of revenue from a year ago, and the cost of providing service rose by 4.6 percentage points by our math. Computer memory components run inside the sequencers to process genetic data, and the company has only secured memory supply through the end of 2026.
What to watch: gross margin excluding one-offs in the first quarter of 2027, after the Vega factory move is scheduled to end. If the margin stays near 36%, computer memory inflation is eating up the factory savings.
Risks this quarter didn't answer
Five standing items — including whether Europe, the Middle East and Africa (EMEA) is a lasting growth driver or a one-off spike from a national project — cannot be read from the earnings release alone.
- Regional sales (EMEA, Americas, Asia-Pacific): not in the release; the quarterly Form 10-Q filing will show whether EMEA held its 52% growth or slowed like Asia-Pacific.
- Clinical customer sales in dollars: missing for a sixth quarter; the release names new partners but gives no dollar revenue for hospital work.
- Academic and government funding in the Americas: not discussed in the release text; conference call commentary will show whether US research budgets improved.
- Average selling prices on multi-machine orders: the release gives unit counts (15 Revio, 35 Vega) without breaking out pricing per unit.
- Remaining performance obligations (contracted backlog): disclosed only in the Form 10-Q footnotes, so the quarterly move is not yet readable.
💲 Other KPIs
Deferred revenue — cash customers have paid for service and products not yet delivered — rose 11.0% from last quarter and 5.8% from a year ago by our math. That reverses a 5.5% annual decline in the second quarter and moves ahead of the 5.5% rise in reported sales.
Inventory dipped by $0.8 million from the second quarter after jumping in the first half on early purchases of computer memory and the move to build Vega machines in-house. Even with the small dip, stock on hand remains 22.3% higher than at the end of 2025 while nine-month sales rose 1.2%.
The average number of shares rose 3.5% from a year ago because the sequencing group pays employees partly in stock, adding $8.0 million of share-based pay in the quarter. PacBio does not buy back shares.
🔮 Guidance
Cut. The company trimmed $5 million from the top of the range, leaving full-year sales down 1.6% at the middle of the plan by our math. By our math, that leaves about $40.8 million for the fourth quarter, or an 8.7% drop from a year ago. It is the third cut in three quarters: -$2.5M, -$10.0M, -$2.5M at the middle.
❓ Key Questions
Why did consumable sales fall with two-thirds on SPRQ-Nx?
Two-thirds of the Revio fleet upgraded to SPRQ-Nx software and the new kits made up over half of Revio consumable sales, yet total consumable revenue slipped 2.3% from a year ago. How much extra testing volume are upgraded accounts actually running against the 30% price cut?
Did the full-year margin, cost and cash targets hold?
The release updated the full-year revenue outlook to $155–160 million but did not mention the prior targets for gross margin (35–37%), operating expenses ($215–220 million) or year-end cash ($175–185 million). Are all three still in place after the finance chief's exit?
How much did clinical and European sales bring in?
Management reorganised the sales force around hospitals and relied on European growth of 52% last quarter, while Asia-Pacific fell 45%. What were third-quarter sales in each region and what was hospital revenue in dollars rather than shipment percentages?
What will computer memory cost in 2027?
High computer memory prices helped push gross margin excluding one-offs down 6 percentage points to 36%, and pre-purchased inventory covers only 2026. What memory cost is built into the 2028 cash-breakeven plan once current stock runs out?